​

Ironwood Pharmaceuticals (IRWD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

IRWD Stock Forecast

Ironwood Pharmaceuticals (IRWD) stock forecast, based on 29 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $7.00 and a low of $1.00. This represents a 400.00% increase from the last price of $0.80.

- $3 $6 $9 $12 $15 High: $7 Avg: $4 Low: $1 Last Closed Price: $0.8

IRWD Stock Rating

Ironwood Pharmaceuticals stock's rating consensus is Hold, based on 29 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (37.93%), 15 Hold (51.72%), 3 Sell (10.34%), and 0 Strong Sell (0.00%).

Hold
Total 29 0 3 15 11 Strong Sell Sell Hold Buy Strong Buy

IRWD Price Target Upside V Benchmarks

TypeNameUpside
StockIronwood Pharmaceuticals400.00%
SectorHealthcare Stocks 18.80%
IndustrySpecialty & Generic Drug Manufacturers Stocks28.72%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$6.25
Last Closing Price$0.80$0.80$0.80
Upside/Downside--681.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 25--4--4
Jun, 25--4--4
May, 251-5--6
Apr, 25231--6
Mar, 25231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2025Faisal KhurshidLeerink Partners$1.00$0.6553.85%25.00%
Jan 31, 2025Mohit BansalWells Fargo$7.00$2.34199.15%775.00%
Sep 09, 2024Faisal KhurshidLeerink Partners$5.00$4.5110.86%525.00%
Aug 09, 2024Mohit BansalWells Fargo$12.00$4.05196.30%1400.00%
May 22, 2024David AmsellemPiper Sandler$18.00$6.82163.93%2150.00%
May 22, 2024Mohit BansalWells Fargo$14.00$6.78106.49%1650.00%
Apr 22, 2022David AmsellemPiper Sandler$16.00$12.1831.36%1900.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 16, 2025Craig-HallumHolddowngrade
Apr 15, 2025JefferiesHolddowngrade
Apr 14, 2025CitigroupMarket Performdowngrade
Jan 31, 2025Wells FargoOverweightOverweighthold
Oct 01, 2024JMP SecuritiesMarket OutperformMarket Outperformhold
Aug 09, 2024Wells FargoOverweightOverweighthold
May 22, 2024Piper SandlerOverweightOverweighthold
May 22, 2024Wells FargoOverweightOverweighthold
Aug 16, 2022Wells FargoEqual-WeightEqual-Weighthold
Apr 22, 2022Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.67$3.26$1.13$-6.45$0.82----
Avg Forecast$0.68$3.26$0.97$-5.85$0.10$0.23$0.81$0.70$1.12
High Forecast$0.76$3.64$1.06$-5.45$0.11$0.43$1.02$0.80$1.28
Low Forecast$0.60$2.87$0.88$-6.24$0.09$0.14$0.60$0.61$0.98
Surprise %-1.47%-16.49%10.26%720.00%----

Revenue Forecast

$300M $380M $460M $540M $620M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$389.52M$413.75M$410.60M$442.74M$351.41M----
Avg Forecast$383.96M$407.40M$411.69M$442.86M$353.31M$338.35M$416.18M$586.60M$540.00M
High Forecast$419.26M$444.86M$440.55M$448.65M$355.44M$379.22M$463.03M$652.64M$600.80M
Low Forecast$349.23M$370.55M$381.04M$438.73M$350.93M$309.86M$375.20M$528.84M$486.83M
Surprise %1.45%1.56%-0.27%-0.03%-0.54%----

Net Income Forecast

$-2B $-1B $-500M $0 $500M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$106.18M$528.45M$175.06M$-1.00B$130.75M----
Avg Forecast$74.32M$357.75M$203.32M$-1.00B$15.69M$32.76M$125.57M$109.80M$174.09M
High Forecast$89.18M$429.30M$243.98M$-801.79M$17.82M$66.55M$158.13M$124.73M$199.57M
Low Forecast$59.45M$286.20M$162.65M$-1.20B$13.55M$22.19M$93.02M$94.88M$151.80M
Surprise %42.87%47.71%-13.90%-733.54%----

IRWD Forecast FAQ

Is Ironwood Pharmaceuticals stock a buy?

Ironwood Pharmaceuticals stock has a consensus rating of Hold, based on 29 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 15 Hold, 3 Sell, and 0 Strong Sell, reflecting a consensus that Ironwood Pharmaceuticals is a neutral investment for most analysts.

What is Ironwood Pharmaceuticals's price target?

Ironwood Pharmaceuticals's price target, set by 29 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $1 at the low end to $7 at the high end, suggesting a potential 400.00% change from the previous closing price of $0.8.

How does Ironwood Pharmaceuticals stock forecast compare to its benchmarks?

Ironwood Pharmaceuticals's stock forecast shows a 400.00% upside, outperforming the average forecast for the healthcare stocks sector (18.80%) and outperforming the specialty & generic drug manufacturers stocks industry (28.72%).

What is the breakdown of analyst ratings for Ironwood Pharmaceuticals over the past three months?

  • July 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 16.67% Strong Buy, 0% Buy, 83.33% Hold, 0% Sell, 0% Strong Sell.

What is Ironwood Pharmaceuticals’s EPS forecast?

Ironwood Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.23, marking a -71.95% decrease from the reported $0.82 in 2024. Estimates for the following years are $0.81 in 2026, $0.7 in 2027, and $1.12 in 2028.

What is Ironwood Pharmaceuticals’s revenue forecast?

Ironwood Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $338.35M, reflecting a -3.72% decrease from the reported $351.41M in 2024. The forecast for 2026 is $416.18M, followed by $586.6M for 2027, and $540M for 2028.

What is Ironwood Pharmaceuticals’s net income forecast?

Ironwood Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $32.76M, representing a -74.95% decrease from the reported $130.75M in 2024. Projections indicate $125.57M in 2026, $109.8M in 2027, and $174.09M in 2028.